EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Dopamine D2 Receptor Agonists as Modulators of VEGF ‐A‐Driven Angiogenesis: Mechanisms, Clinical Evidence, and Translational Opportunities

Venu Akkanapally, Aman Kumar, Inemai Ezhil, Manas Ranjan Sahu, Xue-Feng Bai, Kamal S Pohar, Sujit Basu iD

The FASEB Journal · 2026

DOI: 10.1096/fj.202600843r ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FASEB Journal, 2026. Verfasst von Venu Akkanapally und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor A, Receptors, Dopamine D2, Neovascularization, Pathologic, Dopamine Agonists. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (The James) to Sujit Basu, National Cancer Institute, Congressionally Directed Medical Research Programs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Angiogenesis mediated by vascular endothelial growth factor A (VEGF‐A) is essential for physiological vascular remodeling but also drives pathological processes, including tumor growth, ocular neovascularization, and inflammation. Emerging evidence has revealed that dopamine D2 receptor (DRD2) activation is a key inhibitory pathway that counterbalances VEGF‐A‐dependent endothelial activation and vascular permeability. This review integrates current mechanistic insights into the effects of DRD2 agonists on endothelial signaling, focusing on their ability to suppress VEGF‐A‐induced proangiogenic signaling cascades. Preclinical and translational studies have demonstrated that DRD2 agonists attenuate aberrant angiogenesis, promote vascular normalization, and mitigate VEGF‐A‐induced vascular leakage in diverse pathological contexts, including malignancy, ovarian hyperstimulation syndrome, endometriosis, and inflammatory lung injury. Particular attention is given to the emerging model of tumor‐derived VEGF‐A inducing DRD2 expression within the tumor endothelium, establishing a reciprocal paracrine feedback loop with potential biomarker relevance. Finally, the clinical safety profile and pharmacologic repositioning of DRD2 agonists are evaluated, and priorities for translational research are outlined to refine dosing, scheduling, and patient selection strategies in precision antiangiogenic therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor AReceptors, Dopamine D2Neovascularization, PathologicDopamine AgonistsAngiogenesisHumansAnimalsSignal TransductionTranslational Research, BiomedicalNeoplasms

Substanzen

Vascular Endothelial Growth Factor AReceptors, Dopamine D2Dopamine Agonists

Autor:innen und Institutionen

  • Department of Pathology, Ohio State University, Columbus, Ohio, USA.
  • Pharmaceutical Sciences, Shenzhen University of Advanced Technology, Shenzhen, Guangdong, China.
  • Department of Urology, University of Cincinnati, Cincinnati, Ohio, USA.
  • Division of Medical Oncology, Department of Internal Medicine, Ohio State University, Columbus, Ohio, USA.
  • Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA.

ORCID-Profile: Sujit Basu

Förderung

  • Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (The James) to Sujit Basu
  • National Cancer Institute
  • Congressionally Directed Medical Research Programs
  • Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Zitieren

APA

Akkanapally, V., Kumar, A., Ezhil, I., Sahu, M. R., Bai, X. F., Pohar, K. S., & Basu, S. (2026). Dopamine D2 Receptor Agonists as Modulators of VEGF ‐A‐Driven Angiogenesis: Mechanisms, Clinical Evidence, and Translational Opportunities. The FASEB Journal. https://doi.org/10.1096/fj.202600843r

Vancouver

Akkanapally V, Kumar A, Ezhil I, Sahu MR, Bai XF, Pohar KS, et al. Dopamine D2 Receptor Agonists as Modulators of VEGF ‐A‐Driven Angiogenesis: Mechanisms, Clinical Evidence, and Translational Opportunities. The FASEB Journal. 2026. doi:10.1096/fj.202600843r

BibTeX
@article{Akkanapally2026,
  author = {Akkanapally, Venu and Kumar, Aman and Ezhil, Inemai and Sahu, Manas Ranjan and Bai, Xue-Feng and Pohar, Kamal S and Basu, Sujit},
  title = {Dopamine D2 Receptor Agonists as Modulators of VEGF ‐A‐Driven Angiogenesis: Mechanisms, Clinical Evidence, and Translational Opportunities},
  journal = {The FASEB Journal},
  year = {2026},
  doi = {10.1096/fj.202600843r}
}
Kostenlos starten →